Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia.

Veloso, Carlos E; Vianna, Raul N; Pelayes, David E; Nehemy, Márcio B

Veloso, Carlos E; Vianna, Raul N; Pelayes, David E; Nehemy, Márcio B.

Affiliation

Veloso CE; Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil. cerveloso@hotmail.com

Ophthalmic Res ; 49(4): 205-8, 2013.

Article in En | MEDLINE | ID: mdl-23364325

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Retinal Telangiectasis/drug therapy; Bevacizumab; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Retinal Telangiectasis/classification; Retinal Telangiectasis/diagnosis; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Visual Acuity/physiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Retinal Telangiectasis / Antibodies, Monoclonal, Humanized Type of study: Diagnostic_studies / Observational_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Ophthalmic Res Year: 2013 Type: Article Affiliation country: Brazil

Fulltext

XML

PubMed Links

Search on Google